Literature DB >> 10705158

Paroxysmal nocturnal haemoglobinuria: a replacement of haematopoietic tissue?

H Schrezenmeier1, A Hildebrand, M Rojewski, H Häcker, H Heimpel, A Raghavachar.   

Abstract

Acquired somatic mutations of the PIG-A gene lead to deficient expression of glycosyl-phosphatidyl-inositol-anchored proteins (GPI-AP) by haematopoietic cells and play a causative role in the pathogenesis of paroxysmal nocturnal haemoglobinuria (PNH). However, PIG-A mutations do not explain how the defective PNH clone can expand. It was hypothesized that a selection process conferring a relative advantage to the GPI-AP-deficient population is required. Since GPI-AP-deficient cells are also detectable in a substantial proportion of patients with otherwise typical aplastic anaemia (AA), the mechanisms inducing bone marrow failure might selectively spare the GPI-deficient cells. In order to examine the growth characteristics of GPI-AP-deficient cells in more detail, we performed repeated analyses of GPI-AP expression on peripheral blood cells in 41 patients with AA. We observed four patterns of the course of GPI-AP-deficient populations: (1) 13 patients showed normal expression of GPI-AP in the first analysis and in at least two follow-up studies at a median time of 709 days after the first analysis. (2) Secondary evolution of a GPI-AP-deficient population was a rare event. Only 4 patients with initially normal GPI-AP expression developed a GPI-AP-deficient population during follow up after immunosuppressive treatment. (3) Persistence of GPI-AP-deficient cells was observed in 16 patients during a median follow-up time of 774 days. However, in some patients, the size of the GPI-AP-deficient population increased substantially. (4) Disappearance of a GPI-AP-deficient population was observed in 8 patients. The time course of GPI-AP expression in relation to the treatment suggests that therapeutic interventions might modulate the ratio of normal versus GPI-AP-deficient haematopoiesis. Overall, these data argue against an 'absolute growth advantage' of GPI-AP-deficient cells. Our data are consistent with the hypothesis that haematopoietic failure caused by damage to normal haematopoiesis allows the outgrowth of a GPI-AP-deficient population. Thus, in at least some patients GPI-AP-deficient cells might pre-exist at a very low percentage and replace haematopoiesis after an insult to the normal cells. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10705158     DOI: 10.1159/000041003

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  5 in total

1.  Diagnostic significance of measurement of the receptor for urokinase-type plasminogen activator on granulocytes and in plasma from patients with paroxysmal nocturnal hemoglobinuria.

Authors:  Weiqiang Gao; Zhaoyue Wang; Xia Bai; Yuyun Li; Changgeng Ruan
Journal:  Int J Hematol       Date:  2002-05       Impact factor: 2.490

Review 2.  Relationship between aplastic anemia and paroxysmal nocturnal hemoglobinuria.

Authors:  Taroh Kinoshita; Norimitsu Inoue
Journal:  Int J Hematol       Date:  2002-02       Impact factor: 2.490

3.  Paroxysmal nocturnal hemoglobinuria (PNH): higher sensitivity and validity in diagnosis and serial monitoring by flow cytometric analysis of reticulocytes.

Authors:  Britta Höchsmann; Markus Rojewski; Hubert Schrezenmeier
Journal:  Ann Hematol       Date:  2011-02-26       Impact factor: 3.673

4.  Paroxysmal nocturnal hemoglobinuria presenting with a left intraventricular thrombus in a patient with prior thymoma and aplastic anemia.

Authors:  Yazan Migdady; Adam J Olszewski
Journal:  Clin Med Insights Oncol       Date:  2011-11-03

5.  The spectrum of paroxysmal nocturnal hemoglobinuria clinical presentation in a Brazilian single referral center.

Authors:  Bruno G P Pires da Silva; Natasha P Fonseca; Luis Fernando B Catto; Gabriel C Pereira; Rodrigo T Calado
Journal:  Ann Hematol       Date:  2022-02-18       Impact factor: 3.673

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.